Elixiron-KY
安立璽榮醫藥股份有限公司
Elixiron-KY is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is EI-001 (Phase 2; recruiting, Non-segmental Vitiligo), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| EI-001 | — | Phase 2; recruiting | Non-segmental Vitiligo | Taiwan, United States | 2026-06-05 | Trial registry |
| PLT012 | — | Phase 1; recruiting | Advanced Malignant Solid Tumor; Solid Tumor Cancer | United States | 2026-07-07 | Trial registry |
| EI-1071 | — | Phase 2; completed | Mild, Moderate, or Severe Alzheimer's Disease | Taiwan | 2026-09-23 | Trial registry |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.